Current concepts and treatment advances in systemic mastocytosis;Actualités sur la compréhension et le traitement des mastocytoses systémiques

Revue de Medecine Interne

Volumn 30, Issue 1, 2009, Pages 25-34

  Georgin Lavialle, S ^a   Barete, S ^b   Suarez, F ^a   Lepelletier, Y ^a   Bodemer, C ^c   Dubreuil, P ^d   Lortholary, O ^c   Hermine, O ^a  

^a CNRS   (France)

^b HÔPITAL TENON   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d INSTITUT PAOLI CALMETTES   (France)

Author keywords

C Kit; D816V; Mastocytosis; Rapamycin; Treatment

Indexed keywords

BORTEZOMIB; BUDESONIDE; CLADRIBINE; COTRIMOXAZOLE; DENILEUKIN DIFTITOX; IMATINIB; LENALIDOMIDE; MIDOSTAURIN; PAROXETINE; RAPAMYCIN; STEM CELL FACTOR; STEM CELL FACTOR RECEPTOR; TANDUTINIB; VALACICLOVIR;

CELL PROLIFERATION; DISEASE CLASSIFICATION; DISEASE COURSE; HISTOPATHOLOGY; HUMAN; IMMUNOCHEMISTRY; MAST CELL; PALLIATIVE THERAPY; PATHOPHYSIOLOGY; SHORT SURVEY; STEM CELL; SYSTEMIC MASTOCYTOSIS;

ADULT; BORONIC ACIDS; CHILD; FORECASTING; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE AGENTS; MASTOCYTOSIS, SYSTEMIC; MUTATION; PROGNOSIS; PROTEASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-KIT; PYRAZINES; SIROLIMUS; STEM CELL TRANSPLANTATION; TRANSDUCTION, GENETIC; WORLD HEALTH ORGANIZATION;

EID: 57849120363     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2008.01.025     Document Type: Short Survey

References (60)

1. Fain O., Stirnemann J., Eclache V., Barete S., Casassus P., Hermine O., et al. Mastocytose systémique. Presse Med 34 9 (2005) 681-687
2. Travis W.D., Li C.Y., Bergstralh E.J., Yam L.T., and Swee R.G. Systemic mast cell disease. Analysis of 58 cases and literature review. Medicine (Baltimore) 67 6 (1988) 345-368
3. Linnekin D. Early signaling pathways activated by c-Kit in hematopoietic cells. Int J Biochem Cell Biol 31 10 (1999) 1053-1074
4. Furitsu T., Tsujimura T., Tono T., Ikeda H., Kitayama H., Koshimizu U., et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest 92 4 (1993) 1736-1744
5. Tsujimura T. Role of c-kit receptor tyrosine kinase in the development, survival and neoplastic transformation of mast cells. Pathol Int 46 12 (1996) 933-938
6. Akin C., and Metcalfe D.D. The biology of Kit in disease and the application of pharmacogenetics. J Allergy Clin Immunol 114 1 (2004) 13-19 quiz 20
7. Feger F., Ribadeau Dumas A., Leriche L., Valent P., and Arock M. Kit and c-kit mutations in mastocytosis: a short overview with special reference to novel molecular and diagnostic concepts. Int Arch Allergy Immunol 127 2 (2002) 110-114
8. Nagata H., Worobec A.S., Oh C.K., Chowdhury B.A., Tannenbaum S., Suzuki Y., et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci USA 92 23 (1995) 10560-10564
9. Garcia-Montero A.C., Jara-Acevedo M., Teodosio C., Sanchez M.L., Nunez R., Prados A., et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 108 7 (2006) 2366-2372
10. Longley Jr. B.J., Metcalfe D.D., Tharp M., Wang X., Tyrrell L., Lu S.Z., et al. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc Natl Acad Sci USA 96 4 (1999) 1609-1614
11. Pignon J.M., Giraudier S., Duquesnoy P., Jouault H., Imbert M., Vainchenker W., et al. A new c-kit mutation in a case of aggressive mast cell disease. Br J Haematol 96 2 (1997) 374-376
12. Akin C., Fumo G., Yavuz A.S., Lipsky P.E., Neckers L., and Metcalfe D.D. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood 103 8 (2004) 3222-3225
13. Frost M.J., Ferrao P.T., Hughes T.P., and Ashman L.K. Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant. Mol Cancer Ther 1 12 (2002) 1115-1124
14. Zhang L.Y., Smith M.L., Schultheis B., Fitzgibbon J., Lister T.A., Melo J.V., et al. A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy. Leuk Res 30 4 (2006) 373-378
15. Hartmann K., Wardelmann E., Ma Y., Merkelbach-Bruse S., Preussner L.M., Woolery C., et al. Novel germline mutation of KIT associated with familial gastrointestinal stromal tumors and mastocytosis. Gastroenterology 129 3 (2005) 1042-1046
16. Marrache F., Memain N., Bonte I., Barete S., Casassus P., de Gennes C., et al. Traitement des mastocytoses systémiques. Rev Med Interne 24 9 (2003) 594-601
17. Larroche C., Chadenat M.L., Chaunu M.P., Abad S., Casassus P., and Dhote R. Accident vasculaire cérébral sur dissection artérielle au cours des mastocytoses systémiques: une association non-fortuite ? À propos de deux cas. Rev Med Interne 26 10 (2005) 820-823
18. Kiszewski A.E., Duran-Mckinster C., Orozco-Covarrubias L., Gutierrez-Castrellon P., and Ruiz-Maldonado R. Cutaneous mastocytosis in children: a clinical analysis of 71 cases. J Eur Acad Dermatol Venereol 18 3 (2004) 285-290
19. Fain O., Stirnemann J., and Lortholary O. Mastocytose systémique. Rev Prat 55 15 (2005) 1629-1636
20. Horny H.P., Sotlar K., and Valent P. Mastocytosis: state of the art. Pathobiology 74 2 (2007) 121-132
21. Sperr W.R., Jordan J.H., Fiegl M., Escribano L., Bellas C., Dirnhofer S., et al. Serum tryptase levels in patients with mastocytosis: correlation with mast cell burden and implication for defining the category of disease. Int Arch Allergy Immunol 128 2 (2002) 136-141
22. Schwartz L.B., and Irani A.M. Serum tryptase and the laboratory diagnosis of systemic mastocytosis. Hematol Oncol Clin North Am 14 3 (2000) 641-657
23. Casassus P., Caillat-Vigneron N., Martin A., Simon J., Gallais V., Beaudry P., et al. Treatment of adult systemic mastocytosis with interferon-alpha: results of a multicentre phase II trial on 20 patients. Br J Haematol 119 4 (2002) 1090-1097
24. Tefferi A., Li C.Y., Butterfield J.H., and Hoagland H.C. Treatment of systemic mast-cell disease with cladribine. N Engl J Med 344 4 (2001) 307-309
25. Akin C., Schwartz L.B., Kitoh T., Obayashi H., Worobec A.S., Scott L.M., et al. Soluble stem cell factor receptor (CD117) and IL-2 receptor alpha chain (CD25) levels in the plasma of patients with mastocytosis: relationships to disease severity and bone marrow pathology. Blood 96 4 (2000) 1267-1273
26. Horny H.P., and Valent P. Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings. Leuk Res 25 7 (2001) 543-551
27. Valent P., Horny H.P., Escribano L., Longley B.J., Li C.Y., Schwartz L.B., et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 25 7 (2001) 603-625
28. Jordan J.H., Walchshofer S., Jurecka W., Mosberger I., Sperr W.R., Wolff K., et al. Immunohistochemical properties of bone marrow mast cells in systemic mastocytosis: evidence for expression of CD2, CD117/Kit, and bcl-x(L). Hum Pathol 32 5 (2001) 545-552
29. Sperr W.R., Escribano L., Jordan J.H., Schernthaner G.H., Kundi M., Horny H.P., et al. Morphologic properties of neoplastic mast cells: delineation of stages of maturation and implication for cytological grading of mastocytosis. Leuk Res 25 7 (2001) 529-536
30. Valent P., Akin C., Sperr W.R., Horny H.P., Arock M., Lechner K., et al. Diagnosis and treatment of systemic mastocytosis: state of the art. Br J Haematol 122 5 (2003) 695-717
31. Escribano L., Diaz-Agustin B., Bellas C., Navalon R., Nunez R., Sperr W.R., et al. Utility of flow cytometric analysis of mast cells in the diagnosis and classification of adult mastocytosis. Leuk Res 25 7 (2001) 563-570
32. Escribano L., Diaz-Agustin B., Lopez A., Nunez Lopez R., Garcia-Montero A., Almeida J., et al. Immunophenotypic analysis of mast cells in mastocytosis: When and how to do it. Proposals of the Spanish Network on Mastocytosis (REMA). Cytometry B Clin Cytom 58 1 (2004) 1-8
33. Pardanani A., Ketterling R.P., Brockman S.R., Flynn H.C., Paternoster S.F., Shearer B.M., et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 102 9 (2003) 3093-3096
34. Hartmann K., and Henz B.M. Mastocytosis: recent advances in defining the disease. Br J Dermatol 144 4 (2001) 682-695
35. Tefferi A., and Gilliland D.G. Oncogenes in myeloproliferative disorders. Cell Cycle 6 5 (2007) 550-566
36. Akin C., and Metcalfe D.D. Systemic mastocytosis. Annu Rev Med 55 (2004) 419-432
37. Pardanani A., Baek J.Y., Li C.Y., Butterfield J.H., and Tefferi A. Systemic mast cell disease without associated hematologic disorder: a combined retrospective and prospective study. Mayo Clin Proc 77 11 (2002) 1169-1175
38. Valent P., Akin C., Escribano L., Fodinger M., Hartmann K., Brockow K., et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 37 6 (2007) 435-453
39. Hauswirth A.W., Simonitsch-Klupp I., Uffmann M., Koller E., Sperr W.R., Lechner K., et al. Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature. Leuk Res 28 3 (2004) 249-257
40. Brumsen C., Hamdy N.A., and Papapoulos S.E. Osteoporosis and bone marrow mastocytosis: dissociation of skeletal responses and mast cell activity during long-term bisphosphonate therapy. J Bone Miner Res 17 4 (2002) 567-569
41. Escribano L., Akin C., Castells M., Orfao A., and Metcalfe D.D. Mastocytosis: current concepts in diagnosis and treatment. Ann Hematol 81 12 (2002) 677-690
42. Valent P., Akin C., Sperr W.R., Escribano L., Arock M., Horny H.P., et al. Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. Leuk Res 27 7 (2003) 635-641
43. Musselman D.L., Lawson D.H., Gumnick J.F., Manatunga A.K., Penna S., Goodkin R.S., et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 344 13 (2001) 961-966
44. Escribano L., Diaz-Agustin B., Nunez R., Prados A., Rodriguez R., and Orfao A. Abnormal expression of CD antigens in mastocytosis. Int Arch Allergy Immunol 127 2 (2002) 127-132
45. Kluin-Nelemans H.C., Oldhoff J.M., Van Doormaal J.J., Van't Wout J.W., Verhoef G., Gerrits W.B., et al. Cladribine therapy for systemic mastocytosis. Blood 102 13 (2003) 4270-4276
46. Pardanani A., Hoffbrand A.V., Butterfield J.H., and Tefferi A. Treatment of systemic mast cell disease with 2-chlorodeoxyadenosine. Leuk Res 28 2 (2004) 127-131
47. Demehri S., Corbin A., Loriaux M., Druker B.J., and Deininger M.W. Establishment of a murine model of aggressive systemic mastocytosis/mast cell leukemia. Exp Hematol 34 3 (2006) 284-288
48. Ma Y., Zeng S., Metcalfe D.D., Akin C., Dimitrijevic S., Butterfield J.H., et al. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 99 5 (2002) 1741-1744
49. Ronnov-Jessen D., Lovgreen Nielsen P., and Horn T. Persistence of systemic mastocytosis after allogeneic bone marrow transplantation in spite of complete remission of the associated myelodysplastic syndrome. Bone Marrow Transplant 8 5 (1991) 413-415
50. Fodinger M., and Mannhalter C. Molecular genetics and development of mast cells: implications for molecular medicine. Mol Med Today 3 3 (1997) 131-137
51. Tefferi A., and Pardanani A. Clinical, genetic, and therapeutic insights into systemic mast cell disease. Curr Opin Hematol 11 1 (2004) 58-64
52. Garton A.J., Crew A.P., Franklin M., Cooke A.R., Wynne G.M., Castaldo L., et al. OSI-930: a novel selective inhibitor of Kit and kinase insert domain receptor tyrosine kinases with antitumor activity in mouse xenograft models. Cancer Res 66 2 (2006) 1015-1024
53. Gleixner K.V., Mayerhofer M., Aichberger K.J., Derdak S., Sonneck K., Bohm A., et al. PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. Blood 107 2 (2006) 752-759
54. Gotlib J., Berube C., Growney J.D., Chen C.C., George T.I., Williams C., et al. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood 106 8 (2005) 2865-2870
55. Corbin A.S., Griswold I.J., La Rosee P., Yee K.W., Heinrich M.C., Reimer C.L., et al. Sensitivity of oncogenic KIT mutants to the kinase inhibitors MLN518 and PD180970. Blood 104 12 (2004) 3754-3757
56. Tanaka A., Konno M., Muto S., Kambe N., Morii E., Nakahata T., et al. A novel NF-kappaB inhibitor, IMD-0354, suppresses neoplastic proliferation of human mast cells with constitutively activated c-kit receptors. Blood 105 6 (2005) 2324-2331
57. Gabillot-Carre M., Lepelletier Y., Humbert M., de Sepuvelda P., Hamouda N.B., Zappulla J.P., et al. Rapamycin inhibits growth and survival of D816V-mutated c-kit mast cells. Blood 108 3 (2006) 1065-1072
58. Carter M.C., Robyn J.A., Bressler P.B., Walker J.C., Shapiro G.G., and Metcalfe D.D. Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis. J Allergy Clin Immunol 119 6 (2007) 1550-1551
59. Tefferi A., Verstovsek S., and Pardanani A. How we diagnose and treat WHO-defined systemic mastocytosis in adults. Haematologica 93 1 (2008) 6-9
60. Damaj G., Bernit E., Ghez D., Claisse J.F., Schleinitz N., Harlé J.R., et al. Thalidomide in advanced mastocytosis. Br J Haematol (2008) Feb 23; [Epub ahead of print]